Keytruda takes on rare skin sarcomas in new trial
NCT ID NCT07007273
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in 17 adults with advanced cutaneous sarcomas (excluding angiosarcoma). Participants receive an IV infusion every 3 weeks. The main goal is to see if tumors shrink, with additional tracking of survival and progression. It is an early study to check if the drug works for this rare cancer type.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
-
Ohio State University Comprehensive Cancer Center
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a new treatment option for advanced cutaneous sarcomas that are hard to treat.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects like immune reactions are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.